StockData
Zenas BioPharma, Inc. logo

Zenas BioPharma, Inc. (ZBIO) income statement

ZBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 1/30
$26.42−1.33 (-4.79%)

Close on Nov 18, 2026Market cap $1.72BP/E –Yield –

Zenas BioPharma, Inc. income statement

Ratios

Latest available, balances at Sep 30, 2026

Profitability, FY2025

Gross margin
–
Operating margin
-5264.0%
Net margin
-5418.1%
Return on equity, FY2025
-136.2%

Financial strength

Current ratio
9.42
Debt to equity
1.05
Debt to assets
33.1%
Cash to current liabilities
277.6%

Valuation

P/E ratio
–
Price to sales
–
Price to book
8.11
Dividend yield
–

See a number that looks wrong?